9H4.F Stock Analysis
9H
Uncovered
LungLife AI Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Lunglife AI, Inc. engages in the development of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence enabled molecular analysis of cancer biomakers in blood.Its diagnostic test, LungLB, is intended to be used as a tool to provide physicians with additional information to help in the decision-making process for people with indeterminate lung nodules. The company is headquartered in Thousand Oaks, California. The company went IPO on 2021-07-08. The principal activity of the Company is a developer of clinical diagnostic solutions for lung cancer. The firm operates in the United States of America. The company is focused on the early detection of lung cancer from a simple blood draw enhanced by artificial intelligence. Its LungLB test is a blood-based tool that has been developed to provide clinicians with the information needed to make informed decisions about the management of lung nodules and lung cancer. The firm's LungLB test is positioned to bring certainty into early stage diagnosis confirming for clinicians whether to refer onto biopsy where the low-dose computed tomography (LDCT) scan reveals suspicious nodules.